The United States Food and Drug Administration's regulatory treatment of peptide compounding and research-grade peptide distribution has undergone significant evolution between 2020 and 2026. The principal regulatory instruments are Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act (DQSA) of 2013, and the FDA's ongoing Bulk Drug Substance (BDS) nomination and categorization process. Researchers and distributors operating in this space must understand the current status of specific peptide compounds under FDA's formal categorization framework.
503A vs. 503B Designations: Scope and Compliance Implications
Section 503A governs traditional compounding pharmacies that compound for specific patient prescriptions. These entities may use bulk drug substances only if the substance appears on FDA's 503A Bulks List (positive list), or qualifies for interim use under applicable interim policy. Section 503B governs outsourcing facilities — registered operations that may produce compounded drugs without patient-specific prescriptions for healthcare facility use. 503B facilities operate under Current Good Manufacturing Practice (CGMP) requirements, including in-process and finished product testing equivalent to pharmaceutical-grade standards: identity, potency, purity, sterility (USP <71>), endotoxin (USP <85>), and particulates. The critical distinction for peptide researchers: a compound's placement on a Category 1 (do not compound) or Category 2 (may compound pending review) list directly determines whether compounding pharmacies can legally produce it, irrespective of research-use classification.
GLP-1R Agonist Scheduling: Semaglutide and Tirzepatide Trajectory
The FDA's 2023–2024 actions regarding semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) represent the most consequential regulatory development for metabolic peptide research supply chains. Both were placed on FDA's shortage list between 2022–2024, permitting 503A/503B compounding. As shortages resolved, FDA issued guidances moving semaglutide to Category 1 (ceased compounding prohibition) in 2024, with tirzepatide following in early 2025. These Category 1 designations do not affect research-grade distribution under separate regulatory frameworks (21 CFR Part 312 for IND-exempt research), but they eliminate compounding pharmacy as a supply source. Research peptide suppliers not operating as compounding pharmacies and distributing exclusively for non-clinical research may operate under different provisions — but must ensure their labeling, documentation, and distribution channels are unambiguous regarding research-only classification.
Bulk Drug Substance Nomination Process and Peptide-Specific Status
FDA's BDS nomination process requires nominating entities to provide: (1) proposed use and rationale for compounding; (2) available safety and efficacy data; (3) clinical need documentation. BPC-157 was nominated for the 503A Bulks List; as of 2025, its status remains on the Candidate List without formal Category placement — meaning compounding pharmacies are in regulatory uncertainty. Selank, Semax, and TB-500 are not on any FDA-approved BDS list and are not formally nominated, placing them in a legally distinct category from FDA's compounding framework. GHK-Cu, as a tripeptide with endogenous human origin, occupies a nuanced position — some formulations may qualify under different regulatory provisions. Researchers must consult current FDA databases directly, as BDS status changes are not always publicly announced with advance notice.
Research-Use Documentation: Required Elements for Non-Clinical Distribution
Distributors of research-grade peptides in the U.S. are not subject to pharmaceutical manufacturing regulations when distributing for non-clinical research purposes — provided documentation clearly establishes research-only use. Required documentation elements include: (1) explicit labeling stating "For research and laboratory use only — not for human consumption"; (2) distributor records establishing purchaser identity and research context; (3) full CoA for each lot, including purity by HPLC, identity by MS, endotoxin by LAL, and water content by Karl Fischer; (4) lot-linked manufacturing records with audit trail. The absence of any of these documentation elements does not simply create a compliance gap — it creates potential for re-classification of the distribution as drug sales without approved NDA, which triggers FD&C Act section 301 violations.
Jurisdiction-Specific Notes and Research Classification
The regulatory frameworks described are specific to U.S. federal jurisdiction (FDA). Researchers operating in the EU, Brazil, Argentina, or Paraguay should consult EMA, ANVISA, ANMAT, and DINAVISA frameworks respectively — which differ substantially in peptide compound classification, import licensing requirements, and GMP equivalency standards. For all jurisdictions, these compounds are for research and laboratory use only. Not for unsupervised human consumption.